Fresenius Medical Care (FMC), the manufacturer of GranuFlo and NaturaLyte, has reported that patients undergoing dialysis treatments with their products are at a six times greater risk of suffering heart attacks than patients using other dialysis products. Fresenius also found that 941 dialysis patients had suffered from cardiac arrest inside Fresenius clinics in 2010 after using GranuFlo and NaturaLyte products.
GranuFlo acid concentrate powder and NaturaLyte liquid acid concentrate contain sodium diacetate, which can cause patients with elevated pre-dialysis bicarbonate levels to experience a bicarbonate overdose during dialysis treatment. High bicarbonate blood levels can result in metabolic alkalosis, or a ph imbalance in the bloodstream. Metabolic alkalosis can lead to severe complications such as heart attack, stroke, low blood pressure, myocardial infarction or sudden death.
Fresenius Medical Care issued this information in an internal memo to FMC-owned dialysis centers, but failed to warn thousands of other physicians working in centers not owned by Fresenius. Fresenius is expected to face thousands of lawsuits from dialysis patients that have been injured after receiving treatment with GranuFlo or NaturaLyte.
If you or a loved one experienced a heart attack after receiving hemodialysis treatment with GranuFlo and NaturaLyte, contact the attorneys at Hissey Kientz, LLP for a free case evaluation. You can reach us by calling toll-free at 1-866-275-4454, or by filling out our free contact form on the right of this page.